Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy |
| |
| Authors: | Asako Kitahara Akinori Ebihara Shohei Obayashi Yukihiro Horio Yoshitaka Ono Tomohiro Yoshikawa Naoki Okada Jun Tanaka Hiroto Takiguchi Naoki Hayama Yoko Ito Tsuyoshi Oguma Ichiro Kuwahira Koichiro Asano |
| |
| Affiliation: | 1.Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan; 2.Division of Pulmonary Medicine, Department of Medicine, Tokai University Tokyo Hospital, Japan |
| |
| Abstract: | A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-stimulating factor (G-CSF) was administered until the recovery of neutropenia, when he developed a high fever, severe hypoxemia, and hypotension accompanied by consolidation in the bilateral lungs. His conditions promptly improved after treatment including hydrocortisone and the primary and metastatic tumors remained regressed for 10 months without further treatment. Post-COVID-19 organizing pneumonia during cancer immunochemotherapy can be aggravated by immune-checkpoint inhibitors and G-CSF. |
| |
| Keywords: | febrile neutropenia granulocyte colony-stimulating factor immune-checkpoint inhibitor severe acute respiratory syndrome coronavirus 2 tumor regression |
|
|
